MSC-based treatments regulate the expression of PPARα and PPARγ to reduce hepatic fat accumulation and mitigate NASH inflammation, among which MSC-derived brown adipocytes are more effective than MSCs and MSC lysate (Lee et al., 2017). Here, PPARA is linked to metabolic dysfunction-associated steatohepatitis.